Long-term observation of Chinese patients with fatty liver disease
Official title: Prospective Cohort Assessing The Prevalence And Progress Of Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) In Chinese Subjects
Run by Humanity and Health Research Centre · NCT03151473 · Data updated 2026-11-12
This study looks at how Non-Alcoholic Fatty Liver Disease and its more serious form affect Chinese patients over 10 years to learn more about their causes, progression, and treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20000 (estimated) |
| Sponsor | Humanity and Health Research Centre Academic / other |
| Locations | 1 site (Hong Kong) |
| Status | Recruiting |
| Started | May 8, 2017 |
| Main results expected | May 31, 2027 |
| Study ends | September 30, 2027 |
| Registry record updated | July 29, 2026 |
| Trial ID | NCT03151473 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who are being managed or treated for NAFL or NASH.
✕Probably not a fit
Patients with significant alcohol consumption, liver cirrhosis, or other chronic inflammatory diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a 10-year observational study focusing on patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and its more severe form, Non-Alcoholic Steatohepatitis (NASH). The study aims to address critical clinical questions that remain unanswered from previous trials, exploring the etiology, natural history, diagnosis, treatment, and prevention of these liver conditions. It will also include a biospecimen repository for future translational studies on genomics and biomarkers of response. The research involves a multidisciplinary and multicenter collaboration to gather comprehensive data over the study period.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of NAFLD and NASH, potentially reducing the risk of severe liver complications in patients.
How similar studies have gone: While there have been studies on NAFLD/NASH, this particular longitudinal observational approach focusing on a specific population is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Males or females aged 18 and older; * Adults being managed or treated for NAFL or NASH; * Be able to communicate meaningfully with the Investigator and be legally competent to provide written informed consent. Exclusion Criteria: * Incompetent to understand and/or sign the informed consent; * Ethanol consumption exceeding more than 14 standard beverages per week for males and more than 7 standard beverages per week for female; * Causes for secondary hepatic fat accumulation such as significant alcohol consumption, medications, Wilson's disease, viral infections, starvation or parenteral nutrition, among others, and conditions associated with microvesicular steatosis * Diagnosis of liver cirrhosis and/or hepatocellular carcinoma; * Diagnosis of chronic inflammatory disease (i.e. inflammatory bowel disease, rheumatoid arthritis, inflammatory lung disease, severe infectious diseases), other than NAFL/NASH.
Where it's running
-
Humanity and Health Medical Centre
Hong Kong, Hong Kong Recruiting
Study contacts
- Study coordinator: Yudong Wang, PhD
- Email: danny.wang@hnhmgl.com
- Phone: (852)28613777
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ECC4703 with Sulfasalazine and Pitavastatin in adults with NAFLD and dyslipidemia
This early study tests whether adding ECC4703 to sulfasalazine and pitavastatin is safe and how the body handles the combination in adults with fatty liver disease and high cholesterol.
-
Taiwan green propolis for MASLD and lipid/metabolic issues
This study tests whether Taiwan green propolis capsules can improve blood lipids and body fat in adults with MASLD compared to a placebo over 12 weeks.
-
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD
This program automatically screens high‑risk adults aged 50–75 in primary care to see if they have advanced liver fibrosis and possible MASLD, using routine blood tests and reflex lab tests without extra work for clinicians.
-
Single-cell and spatial mapping of liver degeneration and regeneration
This project will try to use single-cell and spatial omics on preoperative blood and discarded liver tissue from people having liver surgery or biopsy to map how cells change during fatty liver, HBV infection, fibrosis, and cirrhosis.
-
Testing QX1206 in patients with Type 2 Diabetes and fatty liver disease
This study is testing a new treatment called QX1206 to see if it can help adults with Type 2 diabetes and fatty liver disease manage their blood sugar and improve their health.
-
MRI biomarkers to detect NASH in adults with fatty liver
This project will try MRI measurements to see if they can detect NASH in adults with fatty liver who are already scheduled for a liver biopsy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.